Endocrinology

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

Workplace Diabetes Support Checklist for Clinicians / image credit ©kenishirotie/stock.adobe.com
Diabetes Self-Management at Work: A Checklist for Clinicians

November 7th 2025

Adults with diabetes often face obstacles to optimal disease management in the workplace. Use this checklist in the clinic to help them navigate the barriers.

Administration Anounces Landmark GLP-1 Pricing Agreement with Eli Lilly and Novo Nordisk / image ©K KStock/stock.adobe.com
Administration Anounces Landmark GLP-1 Pricing Agreement with Eli Lilly and Novo Nordisk

November 6th 2025

Oral Semaglutide 25 mg Shows Cardiometabolic Benefits Beyond Weight Loss in OASIS 4 Analysis / image credit ©CLIPAREA_media/Shutterstock.com
Oral Semaglutide 25 mg Shows Cardiometabolic Benefits Beyond Weight Loss in OASIS 4 Analysis

November 6th 2025

The Hidden Toll of Diabetes in the Workplace: Global Survey Data  / image credit ©Yuri/stock.adobe.com
The Hidden Toll of Diabetes in the Workplace: Global Survey Data

November 5th 2025

GLP-1 Receptor Agonist GI Safety Comparable Within the Class, But Exceeds SGLT-2 Inhibitor Risk / image credit/ Elisabetta Patorno, MD, DrPH  Courtesy of Harvard Medical School
GLP-1 Receptor Agonist GI Safety Comparable Within the Class, But Exceeds SGLT-2 Inhibitor Risk

November 4th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.